RhoVac AB reported that the Board has decided to change the structure of the management group and appoints former deputy Chief Executive Officer, Anders Månsson, as new CEO of RhoVac as of 2nd September 2019. Former CEO Anders Ljungqvist remains in the management team as the Chief Operating Officer (COO) with primary responsibility for the implementation of the company's clinical studies and for the further development of CMC. The management team consists of Anders Månsson (CEO), Anders Ljungqvist (COO) and Henrik Stage (CFO). The change in the management team reflects the company's strategic focus, which going forward will be on finding the right acquisition or licensing partner for the further development and commercialization of the drug candidate RV001, for which the phase IIb study in prostate cancer will begin imminently. Anders Månsson was recruited to RhoVac in May earlier this year, as Deputy CEO and Chief Business Officer (CBO). He will retain the role of business officer, but now also in combination with a total responsibility for the RhoVac group as a whole. RhoVac consists of a Swedish parent company (RhoVac AB) and a wholly owned Danish subsidiary (RhoVac ApS). Anders Månsson will hold the CEO position in both companies. Outgoing CEO Anders Ljungqvist will focus on the operational work of the company as Chief Operating Officer (COO) and he will be instrumental in carrying out the important phase IIb study in prostate cancer that the company started in August and that is expected to recruit the first patient imminently. Anders Månsson has a long and solid background in the pharmaceutical and biotech industries. He has previously worked in senior positions in large companies, both in Sweden and abroad, primarily in sales, marketing and business development /M&A. He has a solid track record when it comes to conducting large transactions, both acquisition and licensing deals and divestments. Furthermore, Anders Månsson has experience as the CEO of a subsidiary and as a global division manager in major pharmaceutical groups, and he has both board and CEO experience in the biotech area.